Navigation Links
Roche Diabetes Care and ICW Announce Technology Partnership
Date:9/8/2010

ofessionals."

"The agreement with Roche Diabetes Care represents a culmination of our development efforts to date," explains Peter Kirschbauer, CEO of ICW AG. "Roche Diabetes Care will leverage the ICW eHealth Framework and our successful deployment of the highest security standards for information exchange, as we co-develop new and advanced approaches to sharing relevant diabetes data. We are very pleased to have Roche Diabetes Care as our partner."

About InterComponentWareInterComponentWare AG (ICW) is a leading international eHealth specialist with locations in Germany, Austria, Switzerland and the USA. ICW delivers an interoperable eHealth infrastructure and a range of end-user applications for healthcare professionals and their patients. ICW technology enables organizations to extend their existing information systems, connect with diverse systems, and create a secure patient health record based on aggregated data. ICW has successfully implemented its solutions across Europe and in North America.

Visit online at www.icw-global.com.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chug
'/>"/>

SOURCE InterComponentWare AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership.
2. X-Chem and Roche Enter Into Drug Discovery Collaboration and License Agreement
3. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
4. Cellular Dynamics and Roche Conduct Stem Cells in Drug Discovery and Development Workshop at the Society of Toxicology Annual Meeting
5. EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology
6. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
7. PTC Therapeutics Announces Drug Discovery Collaboration With Roche
8. Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
9. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
10. Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better
11. Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... DNA2.0, the leading synthetic genomics company, announced today a significant ... interface, a customer-friendly site navigation, a database of published synthetic ... with a powerful resource for analyzing DNA and protein sequences. ... ...
... at the Canadian,Diabetes Association Congress, physicians will get ... phase 3b clinical study (LEAD(TM) 6) comparing,the investigational ... liraglutide, a human GLP-1 analog administered once daily ... (as,measured by HbA1c) than exenatide, a GLP-1 mimetic ...
... field called transformation optics may usher in a host ... ultra-powerful microscopes and computers by harnessing nanotechnology and "metamaterials." ... those in Einstein,s theory of general relativity, will be ... 17) in the journal Science . The article ...
Cached Biology Technology:DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 3New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 4New research field promises radical advances in optical technologies 2New research field promises radical advances in optical technologies 3New research field promises radical advances in optical technologies 4
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... mothers-to-be have a remarkable way to protect their unborn ... can cause miscarriage and reactivate the ovulatory cycle, pregnant ... blocking their smell. Researchers from the European Molecular Biology ... nature of this ability. A surge of the chemical ...
... Biology (ASBMB) has announced the recipients of its ... for their outstanding achievements and contributions to science. ... Experimental Biology 2009 Meeting, April 18-22, in New ... NIDDK, National Institutes of Health, will give the ...
... Neurological experts from across the U.S. and other ... Medical Center will discuss the latest findings in basic ... International Fragile X Conference, to be held July 23-27 ... diagnosed with Fragile X also will be attending the ...
Cached Biology News:Pregnant mice block out unwelcome admirers to protect their pups 2ASBMB taps 8 scientists for top awards 2ASBMB taps 8 scientists for top awards 3Researcher helping to pioneer medical therapy for Fragile X Syndrome presents latest findings 2
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Request Info...
... Panomer 9 oligodeoxynucleotides ... are labeled at the ... proprietary Alexa Fluor dyes ... for assessing microarray spot ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: